Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

作者：Sarina Barbara; Castagna Luca; Farina Lucia; Patriarca Francesca; Benedetti Fabio; Carella Angelo M; Falda Michele; Guidi Stefano; Ciceri Fabio; Bonini Alessandro; Ferrari Samantha; Malagola Michele; Morello Enrico; Milone Giuseppe; Bruno Benedetto; Mordini Nicola; Viviani Simonetta; Levis Alessandro; Giordano Laura; Santoro Armando; Corradini Paolo^*

来源：Blood, 2010, 115(18): 3671-3677.

DOI：10.1182/blood-2009-12-253856

Hodgkin lymphoma relapsing after autologous transplantation (autoSCT) has a dismal outcome. Allogeneic transplantation (alloSCT) using reduced intensity conditioning (RIC) is a salvage option, but its effectiveness is still unclear. To evaluate the role of RIC alloSCT, we designed a retrospective study based on the commitment of attending physicians to perform a salvage alloSCT; thus, only Hodgkin lymphoma patients having human leukocyte antigen-typing immediately after the failed autoSCT were included. Of 185 patients, 122 found an identical sibling (55%), a matched unrelated (32%) or a haploidentical sibling (13%) donor; 63 patients did not find any donor. Clinical features of both groups did not differ. Two-year progression-free (PFS) and overall survival (OS) were better in the donor group (39.3% vs 14.2%, and 66% vs 42%, respectively, P < .001) with a median follow-up of 48 months. In multivariable analysis, having a donor was significant for better PFS and OS (P < .001). Patients allografted in complete remission showed a better PFS and OS. This is the largest study comparing RIC alloSCT versus conventional treatment after a failed autoSCT, indicating a survival benefit for patients having a donor. (Blood. 2010; 115(18):3671-3677)

• 出版日期2010-5-6